Early-Onset Neonatal Sepsis
9
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
33%
3 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
NICU Antibiotics and Outcomes Trial
Individualized Duration of Antibiotic Treatment in Early Onset Infection in Newborns.
Presepsin to Safely Reduce Antibiotics in Preterm Infants
Efficacy And Safety Of Short Course Antibiotic Therapy In Preterm Neonates With Early Onset Sepsis
Selective Antibiotics When Symptoms Develop Versus Universal Antibiotics for Preterm Neonates
Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations
Predicting EONS in PPROM Patients
PROcalcitonin and Presepsin-guided Decision for Antibiotic Prophylaxis of EOS
Utility of Placental/Umbilical Cord Blood in Early Onset Neonatal Sepsis in Very Low Birth Weight Infants